Skip to content

Effect and mechanism exploration of DLPFC stimulation by rTMS on dual-task walking ability in people with stroke

Effect and mechanism exploration of DLPFC stimulation by rTMS on dual-task walking ability in people with stroke

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066237
Enrollment
Unknown
Registered
2022-11-29
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

The experimental group:rTMS for 3 weeks , The treatment parameters are: frequency of 5Hz, stimulation time of 10 seconds, 50 stimuli, 24 repetitions, pulse interval time of 30 seconds (total stimulus
The control group:rTMS for 3 weeks, The treatment parameters are: frequency of 5Hz, stimulation time of 10 seconds, 50 stimuli, 24 repetitions, pulse interval time of 30 seconds (total stimulus number

Sponsors

The Second People’s Hospital of Kunming
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic criteria for cerebral infarction or cerebral hemorrhage in the key points for diagnosis of various major cerebrovascular diseases in China 2019 formulated by the vascular diseases group of the neurology branch of the Chinese Medical Association; 2. Aged between 30 and 80; 3. First onset and course of disease more than 6 months; 4. Unilateral stroke must be confirmed by brain computed tomography or magnetic resonance imaging; 5. Able to execute simple instructions; 6. Be able to walk at least 10 meters independently.

Exclusion criteria

Exclusion criteria: 1. Other nervous system diseases other than stroke (including craniocerebral trauma); 2. Cerebellar or brainstem injury; 3. Subjects with TMS contraindications, such as wearing cardiac pacemakers, intracranial metal implants or skull defects, previous history of epilepsy, pregnancy, etc; 4. Severe cognitive or speech impairment; 5. Complicated with dysfunction of heart, lung, liver, kidney and other important organs or other serious physical diseases; 6. Refuse to participate in the trial or sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
10 m walking test;Fugl-Meyer Assessment Scores;Modified Rankin Scale, mRS;Timed up and go test;Balance function;Balance effenicy;

Secondary

MeasureTime frame
Overall cognitive function;Executive function;attention;memory;Daily living ability;Daily living ability;Ability to participate in daily activities;Fall incident;

Countries

China

Contacts

Public ContactYang Lei

The Second People’s Hospital of Kunming

leon_yang30@163.com13529435568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 26, 2026